Sujets)
Adulte , Troubles du rythme cardiaque/traitement médicamenteux , Troubles du rythme cardiaque/étiologie , Femelle , Humains , Lettre , Lidocaïne/analogues et dérivés , Lidocaïne/usage thérapeutique , Épanchement péricardique/complications , Tachycardie ventriculaire/traitement médicamenteux , Tachycardie ventriculaire/étiologieRésumé
AIMS: To compare the performance of monoethylglycinexylidide (MEGX) test and conventional liver function tests (LFT) in differentiating between healthy volunteers and patients with different severity of liver cirrhosis, as judged using Child-Pugh (CP) classification. METHODS: One hundred and four patients with cirrhosis (CP class A, 47; B, 32; C, 25) and 25 healthy volunteers were studied between January 2005 to June 2006. In these subjects, conventional LFT were done, and serum specimens collected 15, 30 and 60 minutes after lidocaine injection were analyzed for MEGX. RESULTS: Conventional liver function tests showed minor differences between healthy volunteers and patients with Child class A, whereas these discriminated well between patients with Child class C and healthy volunteers. The changes in ALT, AST, bilirubin, albumin, AP and PT values were statistically significant in CP class B and C but not in class A when compared with healthy volunteers. MEGX concentration at 60 min was significantly higher in healthy volunteers (131.2 ng/mL) as compared to patients with cirrhosis (CP A - 51.3 ng/mL; CP B - 37.1 ng/mL; CP C - 17.3 ng/mL). There were significant differences (p <0.001) among all four groups (healthy volunteers and patients with CP classes A, B and C) for MEGX concentrations at each time point. MEGX test correlated well with CP scores (p <0.0001). CONCLUSION: MEGX test is a useful marker to stratify patients with liver cirrhosis based on liver function.
Sujets)
Adulte , Sujet âgé , Marqueurs biologiques/sang , Études cas-témoins , Femelle , Humains , Lidocaïne/analogues et dérivés , Cirrhose du foie/sang , Tests de la fonction hépatique , Mâle , Adulte d'âge moyen , Sensibilité et spécificité , Indice de gravité de la maladieSujets)
Humains , Femelle , Grossesse , Anesthésiques locaux/sang , Chromatographie en phase liquide à haute performance/méthodes , Spectrophotométrie , Sang foetal/effets des médicaments et des substances chimiques , Échange foetomaternel/effets des médicaments et des substances chimiques , Analyse chimique du sang , Anesthésiques locaux/métabolisme , Bupivacaïne/métabolisme , Bupivacaïne/sang , Lidocaïne/analogues et dérivés , Lidocaïne/métabolisme , Lidocaïne/sang , Mépivacaïne/métabolisme , Mépivacaïne/sangRésumé
Six new substituted acylamides, chemically related to lignocaine were studied for local anaesthetic activity and toxicity in mice, frogs and guinea pigs. Only one of these compounds, w-pyrrolidino 2, 3, 5, 6 tetramethyl acetanilide was found to possess potency comparable to lignocaine with a slightly higher therapeutic index. Study of the S.A.R. of this group indicated that by removal of two methyl groups at position 3 and 5 in the above compound, a local anaesthetic with greater potency than lignocaine may be obtained. Further exploration of the potentialities of a compound having pyrrolidine group as a part of basic side chain is indicated.